US 10,376,598 B2
Targeted therapeutics
Dinesh U. Chimmanamada, Arlington, MA (US); and Weiwen Ying, Lexington, MA (US)
Assigned to MADRIGAL PHARMACEUTICALS, INC., West Conshohocken, PA (US)
Filed by Madrigal Pharmaceuticals, Inc., West Conshohocken, PA (US)
Filed on Apr. 26, 2016, as Appl. No. 15/138,785.
Application 15/138,785 is a continuation of application No. PCT/US2014/062689, filed on Oct. 28, 2014.
Claims priority of provisional application 61/896,416, filed on Oct. 28, 2013.
Prior Publication US 2016/0375142 A1, Dec. 29, 2016
Int. Cl. A61K 49/00 (2006.01); A61K 47/54 (2017.01)
CPC A61K 49/00 (2013.01) [A61K 47/545 (2017.08)] 7 Claims
 
1. A binding moiety-drug conjugate (SDC-TRAP) comprising a binding moiety and an effector moiety,
wherein the binding moiety is ganetespib,
wherein the effector moiety is gemcitabine or and
wherein the SDC-TRAP is selected from the group consisting of SDC-TRAP-309, SDC-TRAP-310, SDC-TRAP-311, SDC-TRAP-312, SDC-TRAP-313, SDC-TRAP-314, SDC-TRAP-315, SDC-TRAP-316, SDC-TRAP-317, SDC-TRAP-318, SDC-TRAP-319, SDC-TRAP-320, SDC-TRAP-321, SDC-TRAP-322, SDC-TRAP-323, SDC-TRAP-324, SDC-TRAP-325, SDC-TRAP-326, SDC-TRAP-327, SDC-TRAP-328, SDC-TRAP-329, SDC-TRAP-330, SDC-TRAP-331, SDC-TRAP-332, SDC-TRAP-333, and SDC-TRAP-334.